Celularity logo
Celularity
CELU | NASDAQ
Chart Builder DCF Calculator
$0.62
-$0.01 (-1.60%)
At close: Nov 16, 2026, 4:00 PM ET
$0.62
$0.00 (-0.15%)
After-hours: Nov 16, 2026, 7:12 PM ET

Celularity Company Profile

Company profile explained

Company Profile

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.

Key Executives

Name Position
Robert Joseph Hariri Founder, Chief Executive Officer & Chairman
John Sprague Acting Chief Financial Officer
Carlos Ramirez SVP of Investor Relations
David Jakob Lemus Treasurer
Kyle Harold Fletcher Chief Legal and Strategy Officer & Corporate Secretary
Sharmila Koppisetti Senior Vice President of Clinical Dev. Immunology & Drug Safety
Steven N. Gordon Chief Operating and Administrative Officer & Director
Tim Wilk Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 29, 2026 PRE 14A Filing
Oct 20, 2026 10-Q Quarterly Report
Oct 20, 2026 10-K/A [Amend] Annual Report
Sep 29, 2026 8-K Current Report
Sep 29, 2026 10-Q Quarterly Report
Sep 28, 2026 SC 13D/A [Amend] Filing
Sep 28, 2026 8-K Current Report
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
View All SEC Filings ➞
Celularity
Celularity logo
Country United States
IPO Date Aug 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 115
CEO Robert Joseph Hariri

Contact Details

170 Park Avenue Florham Park, New Jersey 07932 United States

Stock Details

Ticker Symbol CELU
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001752828
CUSIP Number 151190204
ISIN Number US1511902041
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.